CapVest’s Curium shelves potential $3bn sale amid market volatility

As the JPM and Rothschild process for the French nuclear medicine company is put on hold, attention shifts to Webster Equity-backed PharmaLogic, sources told PE Hub.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this